NCT04506905View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

August 28, 2020

Primary Completion Date

March 22, 2022

Study Completion Date

March 22, 2022

Conditions
Schizophrenia
Interventions
DRUG

MK-8189

MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization

DRUG

Placebo

Oral tablets of dose-matched placebo to MK-8189 according to randomization

Trial Locations (6)

33009

Velocity Clinical Research, Hallandale Beach ( Site 0001), Hallandale

33334

RCA at Fort Lauderdale Behavioral Health Center ( Site 0006), Oakland Park

90806

Collaborative NeuroScience Network ( Site 0008), Long Beach

91206

Parexel ( Site 0004), Glendale

72758-6442

Woodland Research Northwest, LLC ( Site 0002), Rogers

08009

Hassman Research Institute ( Site 0007), Berlin

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04506905 - Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and Healthy Participants (MK-8189-011) | Biotech Hunter | Biotech Hunter